Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Raptiva Withdrawal Shows Comparative Safety Focus From New, Decisive FDA

Apr 13 2009

• By The Pink Sheet

Related Content

FDA’s Josh Sharfstein Takes “Acting” Title Literally

Apr 13 2009

Roche Wins Genentech After Months-Long Battle

Mar 26 2009

Biogen Seeks Tysabri Magic TOUCH Again: REMS Allows Rapid PML Response

Mar 30 2009

Hamburg, Sharfstein Appointments To FDA Shift Focus To Future Plans Of Career Officials

Mar 14 2009

Patient In New Rituxan PML Case Had “Complex” History

Sep 11 2008

Raptiva PML Case Brings Another REMS

Oct 17 2008

Can A REMS Save Raptiva? Tysabri-Style Program Would Mean Restrictions

Feb 23 2009

Can A REMS Save Raptiva?

Feb 19 2009

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window